Daunorubicin (hydrochloride)

Daunorubicin (hydrochloride)

• Product Name Alternative: Daunomycin (hydrochloride); RP 13057 (hydrochloride); Rubidomycin (hydrochloride)
• CAS Number: 23541-50-6
• UNSPSC Description: Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].
• Target Antigen: ADC Cytotoxin; Antibiotic; Apoptosis; Autophagy; Bacterial; DNA/RNA Synthesis; Topoisomerase
• Type: Natural Products
• Related Pathways: Antibody-drug Conjugate/ADC Related;Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage
• Field of Research: Cancer; Infection; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/Daunorubicin-Hydrochloride.html
• Purity: 99.67
• Solubility: DMSO : 50 mg/mL (ultrasonic)|H2O : ≥ 34 mg/mL
• Smiles: O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O.[H]Cl
• Molecular Weight: 563.98
• References & Citations: [1]Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7.|[2]Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4|[3]Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26|[4]Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9.|[5]Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14.|[6]Emeline Bollaert, et al. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. Int J Mol Sci. 2021 May 13;22(10):5153. |[7]Cheng Wu, et al. Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. Eur J Pharm Sci. 2021 Dec 1;167:106013. ACS Nano. 2024 Nov 1.|bioRxiv. 2023 Jan 13.|Cancers (Basel). 2021, 13(5), 1127.|Cell Mol Immunol. 2023 Jan;20(1):51-64.|Curr Pharm Anal. 2018 Jan, 14(1):53-59(7).|Front Biosci (Landmark Ed). 2024 Oct 21;29(10):362.|Front Genet. 05 August 2021.|J Control Release. 2022 Apr 22;346:136-147.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Transl Med. 2022 Jul 6;20(1):304.|Mol Cell Biochem. 2021 Feb;476(2):1233-1243.|Pharmaceutics. 2021, 13(5), 661.|ACS Infect Dis. 2022 Jul 19.|bioRxiv. 2024 July 04.|Cancer Biol Ther. 2020 Apr 2;21(4):320-331.|Cancer Res. 2023 Dec 14.|Cancers (Basel). 2022 Oct 19;14(20):5127.|Cell Oncol. 2022 Aug 29.|Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. |Front Oncol. 2021 Apr 22;11:665763.|Front Oncol. 2021 Apr 6.|Leukemia. 2023 Mar 28.|Microb Drug Resist. 2020 Jan;26(1):81-88.|Oncol Lett. 2020 Jan;19(1):368-378.|Universidad De Salamanca. 2023
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched